SG11201604457XA - Fused heterocyclic compounds as ion channel modulators - Google Patents
Fused heterocyclic compounds as ion channel modulatorsInfo
- Publication number
- SG11201604457XA SG11201604457XA SG11201604457XA SG11201604457XA SG11201604457XA SG 11201604457X A SG11201604457X A SG 11201604457XA SG 11201604457X A SG11201604457X A SG 11201604457XA SG 11201604457X A SG11201604457X A SG 11201604457XA SG 11201604457X A SG11201604457X A SG 11201604457XA
- Authority
- SG
- Singapore
- Prior art keywords
- ion channel
- heterocyclic compounds
- fused heterocyclic
- channel modulators
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361918247P | 2013-12-19 | 2013-12-19 | |
| PCT/US2014/070920 WO2015095370A1 (en) | 2013-12-19 | 2014-12-17 | Fused heterocyclic compounds as ion channel modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201604457XA true SG11201604457XA (en) | 2016-07-28 |
Family
ID=52282986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201604457XA SG11201604457XA (en) | 2013-12-19 | 2014-12-17 | Fused heterocyclic compounds as ion channel modulators |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9416128B2 (en) |
| EP (1) | EP3083608B1 (en) |
| JP (2) | JP6228683B2 (en) |
| KR (1) | KR101918375B1 (en) |
| CN (1) | CN105829301A (en) |
| AU (1) | AU2014364783B2 (en) |
| CA (1) | CA2934517C (en) |
| EA (1) | EA029415B1 (en) |
| ES (1) | ES2691541T3 (en) |
| HK (2) | HK1223357A1 (en) |
| IL (1) | IL245816A0 (en) |
| MX (1) | MX2016008077A (en) |
| NZ (1) | NZ720651A (en) |
| PT (1) | PT3083608T (en) |
| SG (1) | SG11201604457XA (en) |
| WO (1) | WO2015095370A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11261188B2 (en) | 2016-11-28 | 2022-03-01 | Praxis Precision Medicines, Inc. | Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel |
| AU2017364901A1 (en) | 2016-11-28 | 2019-06-13 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2018148745A1 (en) | 2017-02-13 | 2018-08-16 | Praxis Precision Medicines , Inc. | Compounds and their methods of use |
| US11731966B2 (en) | 2017-04-04 | 2023-08-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11278535B2 (en) | 2017-08-15 | 2022-03-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11866439B2 (en) | 2018-05-30 | 2024-01-09 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2835668A (en) * | 1956-06-22 | 1958-05-20 | Us Vitamin Corp | Pyridylethylated benzoxazinediones and process for preparation |
| DE1229537B (en) * | 1962-09-26 | 1966-12-01 | Merck Ag E | Process for the preparation of 3, 4-dihydro-1, 3-benzoxazinonen- (2) |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| IT1264812B1 (en) * | 1993-07-28 | 1996-10-10 | Italfarmaco Spa | THERAPEUTICALLY ACTIVE BENZOSSAZINONIC AND BENZOTHIAZINONIC DERIVATIVES |
| US6995144B2 (en) * | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| WO2008144483A2 (en) * | 2007-05-18 | 2008-11-27 | Armgo Pharma, Inc. | Agents for treating disorders involving modulation of ryanodine receptors |
| AU2009212254A1 (en) | 2008-02-06 | 2009-08-13 | Cv Therapeutics, Inc. | Use of Ranolazine for treating pain |
| JP2012502047A (en) | 2008-09-04 | 2012-01-26 | ギリアード サイエンシーズ， インコーポレイテッド | How to treat atrial fibrillation |
| US20100113514A1 (en) * | 2008-10-30 | 2010-05-06 | Gilead Palo Alto, Inc. | Fused heterocyclic compounds as ion channel modulators |
| JP5527993B2 (en) | 2009-03-31 | 2014-06-25 | 三菱マテリアル株式会社 | Method for producing bis (fluorosulfonyl) imide |
| TWI508726B (en) | 2009-12-21 | 2015-11-21 | Gilead Sciences Inc | Method of treating atrial fibrillation |
| NZ617987A (en) * | 2011-05-10 | 2016-02-26 | Gilead Sciences Inc | Fused heterocyclic compounds as sodium channel modulators |
| TWI478908B (en) * | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | Fused heterocyclic compounds as ion channel modulators |
| WO2014154762A1 (en) * | 2013-03-27 | 2014-10-02 | Boehringer Ingelheim International Gmbh | Dihydroquinazolinone analogues as brd4 inhibitors |
-
2014
- 2014-12-17 MX MX2016008077A patent/MX2016008077A/en unknown
- 2014-12-17 CN CN201480069107.XA patent/CN105829301A/en active Pending
- 2014-12-17 US US14/573,854 patent/US9416128B2/en active Active
- 2014-12-17 AU AU2014364783A patent/AU2014364783B2/en not_active Ceased
- 2014-12-17 WO PCT/US2014/070920 patent/WO2015095370A1/en active Application Filing
- 2014-12-17 EP EP14824313.2A patent/EP3083608B1/en active Active
- 2014-12-17 KR KR1020167019025A patent/KR101918375B1/en active IP Right Grant
- 2014-12-17 SG SG11201604457XA patent/SG11201604457XA/en unknown
- 2014-12-17 EA EA201690972A patent/EA029415B1/en not_active IP Right Cessation
- 2014-12-17 JP JP2016540685A patent/JP6228683B2/en not_active Expired - Fee Related
- 2014-12-17 PT PT14824313T patent/PT3083608T/en unknown
- 2014-12-17 NZ NZ720651A patent/NZ720651A/en not_active IP Right Cessation
- 2014-12-17 CA CA2934517A patent/CA2934517C/en not_active Expired - Fee Related
- 2014-12-17 ES ES14824313.2T patent/ES2691541T3/en active Active
-
2016
- 2016-05-24 IL IL245816A patent/IL245816A0/en unknown
- 2016-10-04 HK HK16111533.3A patent/HK1223357A1/en unknown
- 2016-10-27 HK HK16112411.8A patent/HK1224283A1/en not_active IP Right Cessation
-
2017
- 2017-10-13 JP JP2017199419A patent/JP2018002745A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2016008077A (en) | 2016-10-12 |
| US20150175595A1 (en) | 2015-06-25 |
| AU2014364783A1 (en) | 2016-06-16 |
| HK1224283A1 (en) | 2017-08-18 |
| PT3083608T (en) | 2018-11-09 |
| IL245816A0 (en) | 2016-08-02 |
| CA2934517A1 (en) | 2015-06-25 |
| HK1223357A1 (en) | 2017-07-28 |
| KR101918375B1 (en) | 2018-11-13 |
| EP3083608A1 (en) | 2016-10-26 |
| EP3083608B1 (en) | 2018-07-18 |
| KR20160095158A (en) | 2016-08-10 |
| US9416128B2 (en) | 2016-08-16 |
| JP6228683B2 (en) | 2017-11-08 |
| CN105829301A (en) | 2016-08-03 |
| NZ720651A (en) | 2017-12-22 |
| ES2691541T3 (en) | 2018-11-27 |
| JP2016540810A (en) | 2016-12-28 |
| EA029415B1 (en) | 2018-03-30 |
| EA201690972A1 (en) | 2016-11-30 |
| WO2015095370A1 (en) | 2015-06-25 |
| JP2018002745A (en) | 2018-01-11 |
| CA2934517C (en) | 2018-10-16 |
| AU2014364783B2 (en) | 2017-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1249902A1 (en) | Fused heterocyclic compounds as ion channel modulators | |
| IL273833A (en) | Ion modification | |
| HK1226061A1 (en) | Fused benzoxazepinones as ion channel modulators | |
| HK1224283A1 (en) | Fused heterocyclic compounds as ion channel modulators | |
| HK1184092A1 (en) | Fused heterocyclic compounds as ion channel modulators | |
| EP2862853A4 (en) | Fused heterocyclic compound | |
| EP2865671A4 (en) | Fused heterocyclic compound | |
| EP2857396A4 (en) | Fused heterocyclic compound | |
| HK1223611A1 (en) | Fused piperidine amides as modulators of ion channels | |
| HK1221465A1 (en) | Novel heterocyclic compounds | |
| EP2865672A4 (en) | Fused heterocyclic compound | |
| ZA201508864B (en) | Substituted heterocyclic compounds as crac modulators | |
| GB2517670B (en) | Ion modification | |
| IL246960A0 (en) | Processes for preparing fused heterocyclic ion channel modulators | |
| HK1225728B (en) | Fused heterocyclic compounds as ion channel modulators |